Beyond The Abstract - Pathological Evidence Of Necrosis In Recurrent Renal Mass Following Treatment With Sunitinib

January 25th, 2008 | Category: Cancer

UroToday.com - Sunitinib is a highly potent, selective inhibitor of undoubtful protein tyrosine kinases, including VEGF-R types 1 to 3, PDGF-R- , and PDGF-R-ß. Preclinical info propose that sunitinib has antitumor activity

that may aftereffect from both inhibition of angiogenesis and direct antiproliferative effects on undoubtful tumor cell types.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Renal Carcinoma - Management Of The Small Renal Mass - Evolving Role Of Needle Biopsy In 2008 And Beyond
  • Society Of Urologic Oncology Meeting - Renal Carcinoma - Management Of The Small Renal Mass - Evolving Role Of Needle Biopsy In 2008 And Beyond
  • Sunitinib As First-Line Treatment For Metastatic Renal Cell Carcinoma (mRCC)
  • Management Guidelines For Patients On Sunitinib
  • Safety And Efficacy Of Sunitinib In An Expanded-Access Trial Of Metastatic Renal Cell Carcinoma (mRCC)

    • No comments yet. Be the first.

    Leave a reply